aCROnordic and BGAdvice join forces
December 2007
Broadening competences in drug development
aCROnordic and BGAdvice join forces as of 01 December 2007. The company continues as aCROnordic.
- This is exciting times. Our two companies add positively to each other, and I am very happy about the wider profile of expertise that we now have. This gives us new opportunities and allows us to set new goals, says Søren Strøh, CEO and founder of aCROnordic.
The enclosure fundamentally changes aCROnordic from being a clinical CRO into providing broader competences within drug development. BGAdvice by Birgitte Guldhammer will contribute with extensive experience in cross-organisational project management, and in driving the processes on inventions from product ideas into drug development. The strong clinical research basis in aCROnordic is an added benefit to BGAdvice.
- I am a team player, and in this organisation I find a team of very professional colleagues, who know their business. Together we can offer our customers a total drug development solution in one place, says Birgitte Guldhammer, Managing Director and founder of BGAdvice.
The wider scope of the company comprises servicing the processes all the way from product candidate selection, through evaluation of efficacy and safety studies, registration, and product launch. aCROnordic now offers a full range of drug development services to investors, inventors, and entrepreneurial companies in exploring product ideas by focusing on the fastest, simplest and most efficient way to the market.
In addition, aCROnordic continuously provides flexible and innovative solutions in clinical contract research. These services remain a key activity for national and international customers in the pharmaceutical, biotech, and medical device industry.
Birgitte Guldhammer joins the Management group in aCROnordic as partner and Executive Vice President.
Download in pdf